Incorporating a personalized mRNA vaccine, designed to match an individual’s tumor genetics, into standard immunotherapy substantially boosts survival rates and reduces the recurrence of high-risk skin cancers in patients who have had these malignancies removed.
Global trials that could revolutionize cancer treatment and save countless lives are being led by scientists from Edith Cowan University (ECU).
Clinical Professor Adnan Khattak from ECU’s Centre for Precision Health recently unveiled the newest findings from these trials at the 2023 American Society of Oncology (ASCO) congress in Chicago. The ASCO congress, attracting more than 45,000 participants, is the largest cancer treatment conference worldwide.
After 18 months, cancer-free survival among patients who received the vaccine and the immunotherapy treatment was 78.6 percent, compared to 62.2 percent of those who only received the immunotherapy.
Two years after treatment, only 22.4 percent of patients who had received the vaccine/immunotherapy combination had either died or seen a recurrence of the disease, which rose to 40 percent for the immunotherapy-only group.
Overall, after an average of two years, those who received the vaccine saw a 44 percent lower risk of death or melanoma returning to the same area of the body, and a 65 percent reduction in the risk of death or the cancer returning in a different area of the body.
Crucially, there was no significant increase in rates of adverse side effects.
Professor Khattak said the trial began as a way of trying to address the shortcomings of current treatments.
“The current standard of care is immunotherapy using an antibody known as pembrolizumab,” he said.
“There are two main issues: first, despite having active immunotherapy for stage three melanoma, about half of the patients will relapse at five years.
“And secondly, it’s a very crude approach: currently if I treat 10 new high-risk melanoma patients, I give them the same drug; it’s not rocket science that it’s going to work for some but not others, and some may see side effects and others may not.
“This is the biggest trial to show treatment improves with an individualized approach — and I think research into personal cancer vaccines is going to increase dramatically after this positive study.”
Getting to know you — and your disease
Though vaccines are typically associated with disease prevention, in this instance the mRNA vaccine is used to treat people who have already been diagnosed with melanoma.
Samples of tissue are taken and analyzed to identify neoantigens, proteins that form on cancer cells, and which are unique to an individual’s tumor.
Up to 34 neoantigens may be identified, which are then added to an mRNA molecule and added to a vaccine.
The result is a personalized cancer treatment, with the neoantigens most likely to develop an immune response to help the patient’s body fight cancer.
Professor Khattak said it appeared to be more effective after an extended period of time and required multiple doses.
“In this study, the survival rate between the two groups is the same after 40 weeks, so early relapses happen for both,” he said.
“Some patients have fairly resistant tumors that aren’t going to respond to either of the treatments.
“But after the first 40 weeks, by then the patients have had two or three vaccine doses and the anti-tumor effect really kicks in.
“We see quite a significant proportion of patients relapsing after they finish pembrolizumab, whereas we’re not seeing such late relapses in patients who have done the double treatment because in addition to pembrolizumab, the effect of the vaccine kicks in with a much stronger anti-tumor immune response.”
Next steps
Professor Khattak will soon lead a new global trial of the treatment,
His clinic in Perth, Western Australia recruited the most participants of any site in the world.
“I would like to thank all my patients who took part in this research at a difficult point in their life,” Professor Khattak said.
The new trial will include more participants, some with earlier stages of melanoma.
“Stage two and stage three patients combined constitute quite a significant proportion of patients who could be potentially cured, rather than waiting for them to develop metastatic or advanced disease where most of them will not be curable,” he said.
If successful, the trial could be the starting point of a new approach to cancer treatment, beyond just melanoma.
“This is going to be the stepping stone for a number of trials,” Professor Khattak said.
“Because now they have expanded it into lung cancer, kidney cancers, and also into gastrointestinal cancers.
“This has the potential of becoming a new standard of care moving forward.”
Meeting: 2023 American Society of Oncology
Those looking for details on the trial can contact One Clinical Research.
The research was funded by Moderna, Merck Sharp and Dohme.
News
Ethics in Nanomedicine: Key Issues and Principles
Nanomedicine, a branch of nanotechnology, is revolutionizing healthcare by enabling the manipulation of materials at the nanoscale to diagnose, treat, and prevent diseases. Unlike traditional treatments, nanoparticles (NPs) are highly precise in targeting diseased [...]
A call for robust H5N1 influenza preparedness and response
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a [...]
Mucosal COVID-19 boosters outperform mRNA shots in preventing upper airway infections
In a recent study published in Nature Immunology, a team of researchers from the United States used non-human primate models to compare the protection conferred by an intramuscular booster dose of the bivalent messenger ribonucleic acid [...]
How Space Travel Really Changes Astronauts – From the Inside Out
International team reveals previously unknown effects on physiology that could shape the future of long-duration space missions. Researchers have discovered significant changes in the gut microbiome due to spaceflight, which affects host physiology and [...]
Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure
Melbourne researchers have made a world first breakthrough into creating blood stem cells that closely resemble those in the human body. And the discovery could soon lead to personalized treatments for children with leukemia [...]
Scientists Develop Game-Changing Needle-Free COVID-19 Intranasal Vaccine
A new mucosal COVID-19 vaccine poised to revolutionize the delivery process is especially beneficial for those with a fear of needles. A next-generation COVID-19 mucosal vaccine is set to be a game-changer not only when delivering [...]
Scientists Develop All-in-One Solution To Catch and Destroy “Forever Chemicals”
A new water treatment system developed by UBC researchers efficiently removes and destroys PFAS pollutants using a dual-action catalyst, offering a sustainable and cost-effective solution for water purification challenges. Chemical engineers at the University of [...]
New method accelerates drug discovery from years to months
Researchers from the University of Cincinnati College of Medicine and Cincinnati Children's Hospital have found a new method to increase both speed and success rates in drug discovery. The study, published Aug. 30 in [...]
A new smart mask analyzes your breath to monitor your health
Your breath can give away a lot about you. Each exhalation contains all sorts of compounds, including possible biomarkers for disease or lung conditions, that could give doctors a valuable insight into your health. [...]
Study reveals the role of blood clotting in COVID-19
In a study that reshapes what we know about COVID-19 and its most perplexing symptoms, scientists have discovered that the blood coagulation protein fibrin causes the unusual clotting and inflammation that have become hallmarks [...]
A Novel Cancer Vaccine Combining Nano-11 and ADU-S100
In a recent article published in npj Vaccines, researchers detailed the development of a novel cancer vaccine that combines a plant-derived nanoparticle adjuvant, Nano-11, with a clinically tested STING agonist, ADU-S100. The primary objective was [...]
AI spots cancer and viral infections with nanoscale precision
Researchers have developed an artificial intelligence which can differentiate cancer cells from normal cells, as well as detect the very early stages of viral infection inside cells. The findings, published today in a study [...]
Tiny shards of plastic are increasingly infiltrating our brains, study says
Human brain samples collected at autopsy in early 2024 contained more tiny shards of plastic than samples collected eight years prior, according to a preprint posted online in May. A preprint is a study which has not yet [...]
Scientists Have Discovered Strange DNA in Our Brains – and It Could Be Shortening Our Lives
According to the research, these mitochondrial DNA insertions could be linked to early death. Mitochondria in brain cells frequently insert their DNA into the nucleus, potentially impacting lifespan, as those with more insertions were found to [...]
Watch Out After a Hospital Stay: You Could Be Exposing Your Family to Superbugs
Research indicates hospitals contribute to the local spread of antibiotic-resistant infections. A recent study published in the journal Infection Control & Hospital Epidemiology by the Society for Healthcare Epidemiology of America suggests that family members of [...]
Molecular Trickery: How COVID-19 Silently Sabotages the Human Immune System
Researchers have discovered that SARS-CoV-2 manipulates the human immune system by forcing cells to produce non-functional proteins, hindering the body’s antiviral defenses. This groundbreaking study by teams from prestigious Brazilian universities highlights potential targets for new COVID-19 treatments, [...]